TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31685256

Group type: EXPERIMENTAL
Intervention: Scheimpflug tomography pachymetry map and posterior elevation map patterns
Number of subjects: 96

Group type: COMPARATOR
Intervention: None, 1 or 2, and all 3 pachymetry map and posterior elevation map parameters
Number of subjects: 96

Group type: COMPARATOR
Intervention: None, 1 or 2, and all 3 pachymetry map and posterior elevation map parameters after uncomplicated cataract surgery
Number of subjects: 96
Study: 30260474

Group type: EXPERIMENTAL
Intervention: Paclitaxel, nab-paclitaxel, and ixabepilone
Number of subjects: 468

Group type: COMPARATOR
Intervention: Clinical covariates alone
Number of subjects: 468
Study: 26292026

Group type: EXPERIMENTAL
Intervention: Safe boat technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: I/A tip
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phaco tip
Number of subjects: 90
Study: 26945692

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rectus sheath block
Number of subjects: 50
Study: 25256137

Group type: EXPERIMENTAL
Intervention: MS-20 for 1 week followed by 3 weeks of concomitant MS-20 plus chemotherapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MS-20 treatment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Chemotherapy for 3 weeks
Number of subjects: 143
Study: 21095627

Group type: EXPERIMENTAL
Intervention: Oral ivabradine for 5 days prior to CTCA
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Chronic beta-blockade (atenolol 50mg twice a day for 5 days prior to CTCA)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No additional premedication (Control group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Chronic beta-blockade and ivabradine
Number of subjects: 123
Study: 20081712

Group type: EXPERIMENTAL
Intervention: EROMIA software for electronic recording of patient data
Number of subjects: 0
Study: 18053198

Group type: EXPERIMENTAL
Intervention: Merional administered subcutaneously (s.c.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Merional administered intramuscularly (i.m.)
Number of subjects: 160
Study: 16252535

Group type: EXPERIMENTAL
Intervention: Indirect resin composite onlays
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ceramic onlays
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both indirect resin composite and ceramic onlays
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 11889294

Group type: EXPERIMENTAL
Intervention: Low-volume, pressure-limited ventilation (LVPLV) in group 1 (septic patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-volume, pressure-limited ventilation (LVPLV) in group 2 (nonseptic patients)
Number of subjects: 22
Study: 8996744

Group type: EXPERIMENTAL
Intervention: Oral administration of 450 mg clindamycin (CLDM) three times daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal administration of 2% CLDM phosphate in cream (self-made) 5 g once a day for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral administration of 450 mg CLDM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal administration of 2% CLDM phosphate in cream
Number of subjects: 100
Study: 8217999

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 50 mg/day (n = 103)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 50 mg/day (n = 10)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (n = 105)
Number of subjects: 208
Study: 3618879

Group type: EXPERIMENTAL
Intervention: Brisk walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riding a stationary cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Swimming laps in a pool
Number of subjects: 0
Study: 29659405

Group type: EXPERIMENTAL
Intervention: Topical 2% hydroquinone (HQ) cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 40
Study: 26579704

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 69
Study: 25057035

Group type: EXPERIMENTAL
Intervention: GnRH+ (100 μg GnRH)
Number of subjects: 823

Group type: COMPARATOR
Intervention: GnRH- (no GnRH)
Number of subjects: 823
Study: 22972218

Group type: EXPERIMENTAL
Intervention: Heating on the non-affected hand
Number of subjects: 39
Study: 20395554

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (n = 60)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control (n = 179)
Number of subjects: 239
Study: 18373877

Group type: EXPERIMENTAL
Intervention: Early childhood obesity prevention intervention delivered to first-time parents over the infant's first 18 months of life.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 600
Study: 16001645

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 25
Study: 11802250

Group type: EXPERIMENTAL
Intervention: Airway inflation pressure set to 2.7 kPa
Number of subjects: 32

Group type: COMPARATOR
Intervention: Airway inflation pressure set to 3.0 kPa
Number of subjects: 32
Study: 10887873

Group type: EXPERIMENTAL
Intervention: Standardized protocol for screening delirium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard assessment practices
Number of subjects: 0
Study: 7782725

Group type: EXPERIMENTAL
Intervention: Arabica oil (2 g per day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Robusta oil (2 g per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 11
Study: 1649269

Group type: EXPERIMENTAL
Intervention: Acivicin (AT‐125)
Number of subjects: 32
Study: 6414821

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.d. (oral)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sodium cromoglycate 20 mg q.i.d. (inhalation)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Physician preferences
Number of subjects: 43
Study: 31718678

Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T) therapy aimed at DAS28-ESR remission
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) assessments
Number of subjects: 229
Study: 29268805

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for infants aged <6 months
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Breast-feeding continuation at 1 year
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Breast-feeding continuation at 2 years
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Bottle-feeding prevalence for children aged <2 years
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Solid food introduction for infants aged 6-8 months
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Reason for discontinuation of breast-feeding due to conflict stress
Number of subjects: 477
Study: 27652977

Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (ΔAreamax and ΔSlopemax)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Predictive model using DCE-MRI parameters
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: MRI-predicted pCR
Number of subjects: 170
Study: 24476987

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge (4 mg) with expectancy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nicotine expectancy (without actual nicotine administration)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Exposure to smoking-related stimuli
Number of subjects: 70

Group type: COMPARATOR
Intervention: Women following smoking cue
Number of subjects: 70
Study: 23109475

Group type: EXPERIMENTAL
Intervention: Fresh broccoli soup
Number of subjects: 18

Group type: COMPARATOR
Intervention: Frozen broccoli soup
Number of subjects: 18
Study: 20889139

Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: No periodontal intervention
Number of subjects: 156
Study: 18198648

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI), antibiotics, and short-term pulse therapy with high efficient hormone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antibiotics and hormone pulse therapy
Number of subjects: 80
Study: 16402538

Group type: EXPERIMENTAL
Intervention: Oral pioglitazone (15 mg to 45 mg)
Number of subjects: 5238

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5238
Study: 12402725

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 micrograms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Diamorphine 300 micrograms
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 75
Study: 9502570

Group type: EXPERIMENTAL
Intervention: Glucose-charged dialysate (9.17 mmol/l or 165 mg/dl)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Glucose-free dialysate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Glucose-charged dialysate
Number of subjects: 5
Study: 8569931

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 24
Study: 2757899

Group type: EXPERIMENTAL
Intervention: 1 mg cilazaprilat
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 mg cilazaprilat
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4 mg cilazaprilat
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All doses of cilazaprilat
Number of subjects: 8
Study: 30765

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 31772346

Group type: EXPERIMENTAL
Intervention: Prior to injury
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: After injury
Number of subjects: 410
Study: 31096576

Group type: EXPERIMENTAL
Intervention: Classifier for identifying DAT candidates
Number of subjects: 112
Study: 28806303

Group type: EXPERIMENTAL
Intervention: FFT (Full Fast Track) management
Number of subjects: 263

Group type: COMPARATOR
Intervention: LFT (Limited Fast Track) management
Number of subjects: 263
Study: 25800548

Group type: EXPERIMENTAL
Intervention: ACE‐I/ARB treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic treatment
Number of subjects: 0
Study: 22864470

Group type: EXPERIMENTAL
Intervention: Land exercise
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study: 21248589

Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion plus anterior support (PLF + ALIF)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups (PLF + ALIF and posterolateral fusion)
Number of subjects: 92
Study: 18070786

Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 80 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain bupivacaine 15 mg
Number of subjects: 80
Study: 16960699

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12635350

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 21
Study: 11460275

Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice slurry
Number of subjects: 34

Group type: COMPARATOR
Intervention: Negative control dentifrice slurry
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice
Number of subjects: 34
Study: 9090340

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medication (fluoxetine) plus psychological treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy plus medication
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy plus medication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo plus psychological treatment
Number of subjects: 120
Study: 8224258

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cautery with application of Interceed Adhesion Barrier
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no Interceed application)
Number of subjects: 8
Study: 3708122

Group type: EXPERIMENTAL
Intervention: Multiple-unit pellets (intervention)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-unit tablets (control)
Number of subjects: 12
Study: 31574303

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) plus maximally tolerated guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 614
Study: 30354935

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) plus chemotherapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Patients showing a response to the tumor (complete or partial)
Number of subjects: 112
Study: 27406975

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for 1 year
Number of subjects: 14918
Study: 25022111

Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupoint catgut embedding therapy + acupuncture-moxibustion)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Acupuncture-moxibustion group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined therapy group
Number of subjects: 69
Study: 22533679

Group type: EXPERIMENTAL
Intervention: Epoetin theta (s.c.)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Epoetin beta (s.c.)
Number of subjects: 288
Study: 20547421

Group type: EXPERIMENTAL
Intervention: Needs‐led package of care (therapy based on cognitive behaviour therapy, ethnically matched therapists, advocacy and mentoring; 'rapid access')
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3‐month waiting list control with information on local mental health services ('standard access')
Number of subjects: 40
Study: 18176646

Group type: EXPERIMENTAL
Intervention: Resin Composite (RCO) - Clearfil DC Core Automix
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reforpins (REF) - Two Reforpins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resin Cement (RCE) - Panavia F 2.0
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (DEN) - Non-flared canals
Number of subjects: 40
Study: 15959635

Group type: EXPERIMENTAL
Intervention: Invisalign system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed orthodontic appliances
Number of subjects: 30
Study: 12883205

Group type: EXPERIMENTAL
Intervention: Sirolimus, prednisone, and tacrolimus or cyclosporine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (Control)
Number of subjects: 15
Study: 10559567

Group type: EXPERIMENTAL
Intervention: Denbufylline 25, 50 or 100 mg
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 8903288

Group type: EXPERIMENTAL
Intervention: Routine NGD
Number of subjects: 76

Group type: COMPARATOR
Intervention: Selective NGD
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Selective NGD (no intubation)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Selective NGD (requiring intubation)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 1992187

Group type: EXPERIMENTAL
Intervention: Octreotide, 300 micrograms/24 h for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 11
Study: 6345257

Group type: EXPERIMENTAL
Intervention: Cimetidine for 2 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cimetidine for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 120
Study: 31532795

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids (O-3FA) for 6 months
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 27465634

Group type: COMPARATOR
Intervention: Normoxia (NORM: FiO2 = 0.21)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High hypoxia (HH: FiO2 = 0.13)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH: FiO2 = 0.16)
Number of subjects: 12
Study: 25300348

Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25% urea rinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no rinse)
Number of subjects: 20
Study: 23825432

Group type: EXPERIMENTAL
Intervention: Dyslexic children
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dyslexic children matched for reading performance
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control children matched for reading performance
Number of subjects: 76
Study: 21732049

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 200 min/week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 19521272

Group type: EXPERIMENTAL
Intervention: Expectations of treatment (baseline expectations)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fulfillment of expectations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Actual improvement recorded at 12 months
Number of subjects: 100
Study: 16904480

Group type: EXPERIMENTAL
Intervention: Finasteride (group 1; 88 patients)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Finasteride (group 1)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (group 2; 90 patients)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 178
Study: 15639690

Group type: EXPERIMENTAL
Intervention: Glimepiride plus rosiglitazone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus rosiglitazone
Number of subjects: 40
Study: 11582584

Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Palladium-103 (103Pd)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Prostate brachytherapy
Number of subjects: 34
Study: 9441100

Group type: EXPERIMENTAL
Intervention: Thiacetazone-containing regimen
Number of subjects: 119

Group type: COMPARATOR
Intervention: Rifampicin-containing regimen
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Age > or = 30 years
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Irregular compliance
Number of subjects: 119
Study: 7973221

Group type: EXPERIMENTAL
Intervention: Triangular test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent data monitoring committees
Number of subjects: 0
Study: 2453619

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (PVeBV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard chemotherapy regimen (PVeB)
Number of subjects: 52
Study: 31177388

Group type: EXPERIMENTAL
Intervention: Real cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 26
Study: 29871240

Group type: EXPERIMENTAL
Intervention: Acoustic resonance therapy combined with systemic steroid therapy and conventional drug therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Steroid therapy and conventional drug therapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Acoustic resonance therapy combined with systemic steroid therapy
Number of subjects: 128
Study: 25433294

Group type: EXPERIMENTAL
Intervention: Real-time visual CPR feedback
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Just-in-Time (JIT) CPR training
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Combination of real-time feedback and JIT CPR training
Number of subjects: 324

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Real-time feedback
Number of subjects: 324
Study: 23250834

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Placebo
Number of subjects: 30
Study: 21571595

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48
Study: 17935001

Group type: EXPERIMENTAL
Intervention: Verbal intervening tasks (WAIS‐III Vocabulary or Peabody Picture Vocabulary Test ‐ IIIB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nonverbal intervening tasks (Raven's Standard Progressive Matrices or WAIS‐III Block Design)
Number of subjects: 120
Study: 17243888

Group type: EXPERIMENTAL
Intervention: Perioperative hypnosis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonhypnosis (epidural catheter and narcotics)
Number of subjects: 10
Study: 15380496

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 78
Study: 11580734

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) treatment with low-caloric diet and insulin when appropriate
Number of subjects: 622

Group type: COMPARATOR
Intervention: Routine antenatal care (Control group)
Number of subjects: 622
Study: 9613271

Group type: EXPERIMENTAL
Intervention: Variable performance systems
Number of subjects: 10

Group type: COMPARATOR
Intervention: Constant performance system
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Large nasal catheter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Venturi mask
Number of subjects: 10
Study: 7859806

Group type: EXPERIMENTAL
Intervention: GR122311X 500 mg bid (301 mg bismuth per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GR122311X 1.0 g bid (602 mg bismuth per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) 240 mg bid (431 mg bismuth per day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48